Shuttle Pharmaceuticals Holdings Inc. has announced a significant reduction in salaries for its salaried employees and executive officers. Effective May 21, 2025, the company will implement a 70% salary reduction for key figures, including Interim CEO Christopher Cooper, President and COO Peter Dritschilo, Chief Scientific Officer Mira Jung, Chief Clinical Officer Tyvin Rich, and Vice President of Regulatory Michael P. Vander Hoek. Additionally, Chief Financial Officer Timothy Lorber has agreed to defer 70% of his salary, which will be paid at a later date. This decision reflects the company's current financial adjustments.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-012536), on May 28, 2025, and is solely responsible for the information contained therein.